A biotech hedge fund run out of New York and launched in July last year returned +25% in 2017 and is up 13% YTD to the end of May. That's a total gain of 42%, compared to 5% for the NASDAQ Biotechnology Index (NBI).

According to an email seen by Opalesque, Scoragon Partners LP is a long/short equity fund specializing in biotechnology investment